N/A N=10 A Biologic Joint Replacement Strategy to Treat Patients With Severe Knee Trauma and Post-Traumatic Knee Osteoarthritis
Post-traumatic Osteoarthritis
Primary: Visual Analogue Scale Pain Score — 2.3 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=42 Growth Hormone Therapy in Osteogenesis Imperfecta
Osteogenesis Imperfecta
Primary: Proportion of Subjects Who Met Criteria of Increase in Growth Rate Since Baseline. — 25 Participants
Phase 2 N=20 Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Multiple Myeloma
Primary: Immune Response — 7 Particpants
Phase 2 N=55 Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…
Phase 3 N=637 Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Multiple Myeloma
Primary: Progression-Free Survival (PFS) — 7.63; 6.83 Months — p== 0.0100
Phase 2 N=38 A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Elranatamab · Myeloma · Multiple Myeloma
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) — 1 Participants
Phase 2 N=16 Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Patients With an Objective Response — 31 percentage of patients
Phase 2 N=21 A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma
Relapsed, Refractory or Plateau Phase Multiple Myeloma
Primary: Response Rate [Complete Response (CR) and Partial Response (PR)] — 0; 0; 0; 1 participants
Phase 2 N=57 Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)
Multiple Myeloma
Primary: Overall Response Rate (ORR) - Percentage of Participants With Partial Response or Better With Induction Regimen — 77.2 percentage of participants
Phase 2 N=8 A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Smoldering Multiple Myeloma
Primary: 2 Year Progression Free Percent — 62.5 percentage of participants
N/A N=16 Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma
Multiple Myeloma · Myeloma · Disability Physical
Primary: Intervention Attendance (Feasibility) — 50 percentage of participants
Phase 2 N=60 Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
Multiple Myeloma
Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Phase 2 N=8 Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
Multiple Myeloma
Primary: Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Participants
Phase 2 N=67 Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L
Multiple Myeloma
Primary: Progression Free Survival (PFS) Rate at 2 Years After Enrollment in Untreated Patients With Multiple Myeloma. — 84.6; 83.3 percentage of participants
Phase 2 N=32 Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Refractory Plasma Cell Myeloma · Recurrent Plasma Cell Myeloma
Primary: Number of Patients With Dose-Limiting Toxicities (Phase I) — 1; 1 Participants